在脆性1型糖尿病患者中持续皮下注射奥曲肽的应用。
The use of continuous subcutaneous octreotide infusion in brittle type 1 diabetic patients.
作者信息
Bello F, Falko J M, O'Dorisio T M, Osei K
机构信息
Department of Internal Medicine, Ohio State University Hospitals, Columbus.
出版信息
Diabet Med. 1991 May;8(4):385-7. doi: 10.1111/j.1464-5491.1991.tb01615.x.
Abstract
Two Type 1 diabetic patients with brittle diabetes were successfully treated using continuous SC octreotide (Sandostatin) infusion (200 micrograms 24-h-1) for 6 months and 12 months. When the analogue was discontinued, rapid deterioration in glucose control and ketonuria recurred in one patient and diabetic ketoacidosis in the other. These were corrected after reinstitution of the analogue.
摘要
两名脆性1型糖尿病患者通过皮下持续输注奥曲肽（善宁）（200微克/24小时）成功治疗了6个月和12个月。当停用该类似物后，一名患者血糖控制迅速恶化且再次出现酮尿症，另一名患者则发生糖尿病酮症酸中毒。在重新使用该类似物后这些情况得到纠正。
Zotero 插件